companiesandmarkets.com

Summary: Introduction

This analysis examines the historical and forecast performance for Sepracor in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

Benchmark Sepracor′s performance against key rivals in the ethical pharmaceutical sector
See how the company has achieved profitability following the launches of Xopenex HFA and Lunesta in 2005
Evaluate Sepracor′s long-term growth prospects in the context of the expected 2010 patent expiry of its first product, Xopenex Inhalation Solution

Reports are normally delivered on the same day, via email, if purchased by debit/credit card. Reports purchased by invoice will be released when payment has been received. When you place an order through Google Checkout, Google Checkout will display a price approximation in your local currency. Keep in mind that you'll still be charged in the currency displayed on companiesandmarkets.com. Your debit/credit card company might convert the charge to your local currency and may also add additional fees that are not reflected in the approximate price displayed.

www.companiesandmarkets.com is a central source of market research reports from the world’s leading analysts and report publishers. Companiesandmarkets.com contains a comprehensive range of specialised market research reports from leading publishers for all market sectors.